Oxurion NV
OXUR
Company Profile
Business description
Oxurion NV is a clinical-stage biopharmaceutical company developing next-generation standard-of-care ophthalmic therapies, which are designed to improve and preserve vision in patients with retinal disorders including Geographic Atrophy (GA). The Group’s research and development facilities are located in Belgium. The Company is engaged in the development of drugs to treat blindness diseases.
Contact
Gaston Geenslaan 1
LeuvenB-3001
BELT: +32 16751310
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
11
Stocks News & Analysis
stocks
James Hardie transfers of share listing to New York Stock Exchange
The change is a result of the controversial Azek acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.50 | 91.30 | -1.01% |
| CAC 40 | 7,822.67 | 0.67 | 0.01% |
| DAX 40 | 24,289.51 | 81.42 | -0.33% |
| Dow JONES (US) | 44,342.19 | 142.30 | -0.32% |
| FTSE 100 | 8,992.12 | 19.48 | 0.22% |
| HKSE | 24,960.64 | 134.98 | 0.54% |
| NASDAQ | 20,895.65 | 10.01 | 0.05% |
| Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
| NZX 50 Index | 12,950.36 | 69.96 | 0.54% |
| S&P 500 | 6,296.79 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,664.50 | 92.70 | -1.06% |
| SSE Composite Index | 3,548.35 | 13.87 | 0.39% |